More Medical News
Galenica's kidney drug meets endpoint in trial

ZURICH - Swiss healthcare company Galenica said on Monday that its kidney drug PA21 successfully met primary and secondary endpoints in a late-stage trial, paving the way for gubernatorial

compliancehelp your classification comply with multinational regulations! learn morewww.dataflux.comgb pharmaa full service cro: ricerca clinica farmacovigilanza filings in the United States, Europe and Switzerlan...

More: - Read More

Share |
(Posted in Medical School)
Share and enjoy
  • Digg
  • DZone
  • Netvouz
  • NewsVine
  • Reddit
  • Slashdot
  • StumbleUpon
  • Technorati
  • YahooMyWeb
Entry 1 of 19080
Last Page | Next Page